This week has been insanely busy, especially with the 4 day work week, so I haven't had as much time as usual to post some detailed blogs.
Here's something interesting I came across this week, which may provide some food for thought.
One of the challenges of taking drugs to market faster is more rapid enrollment of clinical trials, hence cutting down the time to get the registration trials ready for the FDA or EMEA submission. One small biotechnology company came up with a novel approach – using the web to effectively provide useful information based on where the sites are and also key words such as TKI or CML resistant etc. I found the site by searching on the T315i mutation, which is what doctors and patients might also search for if they have CML with that aberration.
This is what the site looks like:
ChemGenex is an Australian based company, with offices in California, who submitted an NDA this week:
"For the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. Imatinib, a tyrosine kinase inhibitor (TKI), is the first-line standard of care for patients with CML."
What's interesting about their site, http://www.tkiresistantcml.com is that when you look at the trials, you can download a map of either of the trials. The map provides information on where the centres are, who the PI's are and contact details (email and phone numbers) for physicians to call if they have suitable patients eligible for the study:
As you roll over your cursor on the site or the PDF download (see example here), you get a pop up box with the relevant contact information. Very neat.
These are user friendly ways of communicating relevant information and embracing and extending the knowledge to patients and physicians in a searchable way.
It's good to see companies trying new approaches like this, rather than just sticking the study in the clinicaltrials.gov database and hoping for the best.